Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | farnesyl diphosphate synthase | Starlite/ChEMBL | References |
Leishmania donovani | farnesyl pyrophosphate synthase | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 1 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
ED50 (functional) | = 1 ug kg-1 | Effective dose after subcutaneous administration to TPTX rats for 50% reduction of hypercalcemia | ChEMBL. | 12166945 |
ED50 (functional) | = 1 ug kg-1 | Effective dose in inhibiting osteoclastic bone resorption | ChEMBL. | 12825934 |
IC50 (functional) | = -8.57 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
IC50 (binding) | = -6.6 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
IC50 (binding) | = 0.25 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
IC50 (binding) | = 0.25 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (binding) | = 0.25 uM | Inhibitory activity against Leishmania major Farnesyl diphosphate synthase | ChEMBL. | 14695831 |
IC50 (binding) | = 0.25 uM | Inhibitory activity against farnesyl Pyrophosphate Synthase was determined | ChEMBL. | 14613320 |
IC50 (functional) | = 20.5 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | = 20.5 uM | In vitro growth inhibition against Entamoeba histolytica | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
IC50 (functional) | > 200 uM | In vitro growth inhibition against Plasmodium falciparum | ChEMBL. | 14695831 |
Ki (binding) | = 0.024 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
Ki (binding) | = 0.024 uM | Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand | ChEMBL. | 14613320 |
LD50 (ADMET) | > 727 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
LD50 (ADMET) | > 727 uM | Toxicity evaluated against human nasopharyngeal carcinoma KB cell line | ChEMBL. | 14695831 |
Log IC50 (binding) | = 6.6 | Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M) | ChEMBL. | 14613320 |
Log IC50 (functional) | = 8.56500000000002 | Negative logarithm of inhibitory concentration against bone resorption | ChEMBL. | 12825934 |
TI (ADMET) | > 35.5 | Therapeutic index was expressed as ratio of LD50 for KB cell line to IC50 against Entamoeba histolytica | ChEMBL. | 14695831 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
4 literature references were collected for this gene.